A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.
Publication
, Journal Article
Mikhael, J; Belhadj-Merzoug, K; Hulin, C; Vincent, L; Moreau, P; Gasparetto, C; Pour, L; Spicka, I; Vij, R; Zonder, J; Atanackovic, D; Weng, Q ...
Published in: Blood Cancer J
May 12, 2021
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Blood Cancer J
DOI
EISSN
2044-5385
Publication Date
May 12, 2021
Volume
11
Issue
5
Start / End Page
89
Location
United States
Related Subject Headings
- Treatment Outcome
- Multiple Myeloma
- Middle Aged
- Male
- Humans
- Female
- Drug Resistance, Neoplasm
- Antineoplastic Agents, Immunological
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal
Citation
APA
Chicago
ICMJE
MLA
NLM
Mikhael, J., Belhadj-Merzoug, K., Hulin, C., Vincent, L., Moreau, P., Gasparetto, C., … Leleu, X. (2021). A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. Blood Cancer J, 11(5), 89. https://doi.org/10.1038/s41408-021-00478-4
Mikhael, Joseph, Karim Belhadj-Merzoug, Cyrille Hulin, Laure Vincent, Philippe Moreau, Cristina Gasparetto, Ludek Pour, et al. “A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.” Blood Cancer J 11, no. 5 (May 12, 2021): 89. https://doi.org/10.1038/s41408-021-00478-4.
Mikhael J, Belhadj-Merzoug K, Hulin C, Vincent L, Moreau P, Gasparetto C, et al. A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. Blood Cancer J. 2021 May 12;11(5):89.
Mikhael, Joseph, et al. “A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.” Blood Cancer J, vol. 11, no. 5, May 2021, p. 89. Pubmed, doi:10.1038/s41408-021-00478-4.
Mikhael J, Belhadj-Merzoug K, Hulin C, Vincent L, Moreau P, Gasparetto C, Pour L, Spicka I, Vij R, Zonder J, Atanackovic D, Gabrail N, Martin TG, Perrot A, Bensfia S, Weng Q, Brillac C, Semiond D, Macé S, Corzo KP, Leleu X. A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. Blood Cancer J. 2021 May 12;11(5):89.
Published In
Blood Cancer J
DOI
EISSN
2044-5385
Publication Date
May 12, 2021
Volume
11
Issue
5
Start / End Page
89
Location
United States
Related Subject Headings
- Treatment Outcome
- Multiple Myeloma
- Middle Aged
- Male
- Humans
- Female
- Drug Resistance, Neoplasm
- Antineoplastic Agents, Immunological
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal